A new index of priority symptoms in advanced ovarian cancer

Sally E. Jensen; Sarah K. Rosenbloom; Jennifer L. Beaumont; Amy Abernethy; Paul B. Jacobsen; Karen Syrjala; David Cella

doi:10.1016/j.ygyno.2010.09.025

A new index of priority symptoms in advanced ovarian cancer

Sally E. Jensen, Sarah K. Rosenbloom, Jennifer L. Beaumont, Amy Abernethy, Paul B. Jacobsen, Karen Syrjala, David Cella

Medical Social Sciences

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Objective.: This study sought to develop and examine preliminary validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), a new ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. Methods.: Fifty-one women with advanced ovarian cancer rated the importance of 30 symptoms associated with advanced ovarian cancer. Ten gynecologic oncologists then rated symptoms according to whether they were predominantly disease- or treatment-related. Patient priorities were then reconciled with previously-published clinician priorities for symptom measurement in ovarian cancer. This produced the NFOSI-18. Participants also completed measures of quality of life and performance status to examine preliminary validity of the NFOSI-18. Results.: An 18-item symptom index for advanced ovarian cancer was developed, including three subscales: disease-related symptoms, treatment-related symptoms, and general function/well-being. Lower NFOSI-18 scores indicate greater high-priority symptom burden. Preliminary reliability suggests good internal consistency (α = 0.80). The NFOSI-18 and its subscales were significantly positively associated with quality of life validity criteria. Scores on the NFOSI-18 differed significantly by performance status, with poor performance status associated with lower NFOSI-18 scores. Conclusions.: The NFOSI-18 shows preliminary evidence for reliability and validity as a brief assessment of the most important symptoms associated with treatment for advanced ovarian cancer.

Original language	English (US)
Pages (from-to)	214-219
Number of pages	6
Journal	Gynecologic oncology
Volume	120
Issue number	2
DOIs	https://doi.org/10.1016/j.ygyno.2010.09.025
State	Published - Feb 2011

Funding

Support for the study was provided by grants from the following pharmaceutical companies: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Centocor, Cell Therapeutics, Inc., Genentech, GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Novartis, Ortho Biotech, Pfizer, Sanofi-Aventis and Takeda Pharmaceuticals. The contents represent original work. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated.

Keywords

Ovarian Cancer
Quality of life
Symptom Index

ASJC Scopus subject areas

Obstetrics and Gynecology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2010.09.025

Cite this

@article{e014e92e1a8e461285cccf93d5c5ada8,

title = "A new index of priority symptoms in advanced ovarian cancer",

abstract = "Objective.: This study sought to develop and examine preliminary validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), a new ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. Methods.: Fifty-one women with advanced ovarian cancer rated the importance of 30 symptoms associated with advanced ovarian cancer. Ten gynecologic oncologists then rated symptoms according to whether they were predominantly disease- or treatment-related. Patient priorities were then reconciled with previously-published clinician priorities for symptom measurement in ovarian cancer. This produced the NFOSI-18. Participants also completed measures of quality of life and performance status to examine preliminary validity of the NFOSI-18. Results.: An 18-item symptom index for advanced ovarian cancer was developed, including three subscales: disease-related symptoms, treatment-related symptoms, and general function/well-being. Lower NFOSI-18 scores indicate greater high-priority symptom burden. Preliminary reliability suggests good internal consistency (α = 0.80). The NFOSI-18 and its subscales were significantly positively associated with quality of life validity criteria. Scores on the NFOSI-18 differed significantly by performance status, with poor performance status associated with lower NFOSI-18 scores. Conclusions.: The NFOSI-18 shows preliminary evidence for reliability and validity as a brief assessment of the most important symptoms associated with treatment for advanced ovarian cancer.",

keywords = "Ovarian Cancer, Quality of life, Symptom Index",

author = "Jensen, {Sally E.} and Rosenbloom, {Sarah K.} and Beaumont, {Jennifer L.} and Amy Abernethy and Jacobsen, {Paul B.} and Karen Syrjala and David Cella",

note = "Funding Information: Support for the study was provided by grants from the following pharmaceutical companies: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Centocor, Cell Therapeutics, Inc., Genentech, GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Novartis, Ortho Biotech, Pfizer, Sanofi-Aventis and Takeda Pharmaceuticals. The contents represent original work. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated. ",

year = "2011",

month = feb,

doi = "10.1016/j.ygyno.2010.09.025",

language = "English (US)",

volume = "120",

pages = "214--219",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - A new index of priority symptoms in advanced ovarian cancer

AU - Jensen, Sally E.

AU - Rosenbloom, Sarah K.

AU - Beaumont, Jennifer L.

AU - Abernethy, Amy

AU - Jacobsen, Paul B.

AU - Syrjala, Karen

AU - Cella, David

N1 - Funding Information: Support for the study was provided by grants from the following pharmaceutical companies: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Centocor, Cell Therapeutics, Inc., Genentech, GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Novartis, Ortho Biotech, Pfizer, Sanofi-Aventis and Takeda Pharmaceuticals. The contents represent original work. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated.

PY - 2011/2

Y1 - 2011/2

N2 - Objective.: This study sought to develop and examine preliminary validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), a new ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. Methods.: Fifty-one women with advanced ovarian cancer rated the importance of 30 symptoms associated with advanced ovarian cancer. Ten gynecologic oncologists then rated symptoms according to whether they were predominantly disease- or treatment-related. Patient priorities were then reconciled with previously-published clinician priorities for symptom measurement in ovarian cancer. This produced the NFOSI-18. Participants also completed measures of quality of life and performance status to examine preliminary validity of the NFOSI-18. Results.: An 18-item symptom index for advanced ovarian cancer was developed, including three subscales: disease-related symptoms, treatment-related symptoms, and general function/well-being. Lower NFOSI-18 scores indicate greater high-priority symptom burden. Preliminary reliability suggests good internal consistency (α = 0.80). The NFOSI-18 and its subscales were significantly positively associated with quality of life validity criteria. Scores on the NFOSI-18 differed significantly by performance status, with poor performance status associated with lower NFOSI-18 scores. Conclusions.: The NFOSI-18 shows preliminary evidence for reliability and validity as a brief assessment of the most important symptoms associated with treatment for advanced ovarian cancer.

AB - Objective.: This study sought to develop and examine preliminary validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), a new ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. Methods.: Fifty-one women with advanced ovarian cancer rated the importance of 30 symptoms associated with advanced ovarian cancer. Ten gynecologic oncologists then rated symptoms according to whether they were predominantly disease- or treatment-related. Patient priorities were then reconciled with previously-published clinician priorities for symptom measurement in ovarian cancer. This produced the NFOSI-18. Participants also completed measures of quality of life and performance status to examine preliminary validity of the NFOSI-18. Results.: An 18-item symptom index for advanced ovarian cancer was developed, including three subscales: disease-related symptoms, treatment-related symptoms, and general function/well-being. Lower NFOSI-18 scores indicate greater high-priority symptom burden. Preliminary reliability suggests good internal consistency (α = 0.80). The NFOSI-18 and its subscales were significantly positively associated with quality of life validity criteria. Scores on the NFOSI-18 differed significantly by performance status, with poor performance status associated with lower NFOSI-18 scores. Conclusions.: The NFOSI-18 shows preliminary evidence for reliability and validity as a brief assessment of the most important symptoms associated with treatment for advanced ovarian cancer.

KW - Ovarian Cancer

KW - Quality of life

KW - Symptom Index

UR - http://www.scopus.com/inward/record.url?scp=79251601350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251601350&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.09.025

DO - 10.1016/j.ygyno.2010.09.025

M3 - Article

C2 - 21075440

AN - SCOPUS:79251601350

SN - 0090-8258

VL - 120

SP - 214

EP - 219

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 2

ER -

A new index of priority symptoms in advanced ovarian cancer

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this